2021
Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term
Atamla M, Khoury J, Dabbah I, Kramsky R, Yaacob A, Veitsman E, Saadi T. Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. Clinical And Experimental Hepatology 2021, 7: 258-263. PMID: 34712826, PMCID: PMC8527337, DOI: 10.5114/ceh.2021.109192.Peer-Reviewed Original ResearchDirect antiviral agentsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionQuality of lifeC virus infectionHealth-related qualitySuccessful treatmentVirus infectionAntiviral agentsChronic HCV infectionDAA treatmentExtrahepatic manifestationsHCV infectionLiver diseaseLong termLiver fibrosisObservational studyProfound negative impactNew drugsInfectionHRQLTreatmentAverage timePatientsDrugs
2019
Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection
Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. Journal Of Gastrointestinal Cancer 2019, 51: 584-590. PMID: 31407252, DOI: 10.1007/s12029-019-00293-y.Peer-Reviewed Original ResearchConceptsHepatitis C virusExtrahepatic malignanciesAntiviral agentsParitaprevir/ritonavir/ombitasvirChronic hepatitis C virusRecurrent metastatic breast cancerRecurrent transitional cell carcinomaMethodsFour hundred thirtyChronic HCV infectionDirect antiviral agentsMetastatic breast cancerTreatment of choiceTransitional cell carcinomaPossible relationshipDAA treatmentResultsNine patientsHCV infectionCommon regimenCell carcinomaC virusLaryngeal carcinomaPancreatic adenocarcinomaLung carcinomaBreast cancerUrinary bladder
2018
Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?
Saadi T, Khoury J. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies? Journal Of Clinical Gastroenterology 2018, 52: 353-359. PMID: 28590324, DOI: 10.1097/mcg.0000000000000853.Peer-Reviewed Original ResearchConceptsDirect antiviral agentsAdverse eventsHepatocellular carcinomaAntiviral agentsChronic hepatitis C virus (HCV) infectionParitaprevir/ritonavir/ombitasvirHepatitis C virus infectionDe novo hepatocellular carcinomaLarge clinical trial dataSerum HCV RNAC virus infectionNovo hepatocellular carcinomaTreatment of choiceTransitional cell carcinomaAggressive hepatocellular carcinomaAggressive transitional cell carcinomaClinical trial dataDevelopment of malignancyHCV infectionHCV RNAHCV genotypesLiver diseaseCell carcinomaLaryngeal carcinomaPancreatic adenocarcinoma